The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class ...

The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...

( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first ...

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental There’s a new way for doctors to treat the ...

One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...

Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.

The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.